Lok N S, Lau C P
Department of Medicine, University of Hong Kong, Queen Mary Hospital.
Chest. 1997 Apr;111(4):934-40. doi: 10.1378/chest.111.4.934.
Atrial fibrillation (AF) is associated with impaired exercise capacity. Oxygen uptake (VO2) kinetics determines cardiopulmonary performance during submaximal exercise, which may be impaired in patients with AF.
To study oxygen kinetics and cardiopulmonary performance in patients with AF without structural heart disease and the effects of oral sotalol on these parameters.
Twenty consecutive patients (mean age, 56+/-8 years) with chronic AF were recruited. The protocol design was a randomized, single-blinded, and placebo-controlled trial. Patients received either sotalol or placebo for an 8-week study period, and the alternative treatment in the subsequent period. Cardiopulmonary function tests using constant workload and incremental workload protocols were performed at the end of each phase. Sixteen age-matched normal subjects were included as control subjects.
During constant submaximal exercise, patients with AF had a larger oxygen deficit (425+/-140 mL vs 289+/-80 mL in normal subjects; p<0.05) and the time for achieving 63% of VO2 (mean response time) was also delayed (46+/-15 s vs 33+/-10 s; p<0.05). Compared with normal subjects, patients with chronic AF had a higher maximal exercise heart rate (180+/-34 beats/min vs 153+/-22 beats/min; p<0.05), but a lower maximal VO2 (20+/-4 mL/kg/min vs 26+/-6 mL/kg/min; p<0.05). Oral sotalol lowered the resting (72+/-15 beats/min vs 93+/-22 beats/min; p<0.05) and exercise heart rate compared with placebo (125+/-27 beats/min vs 180+/-34 beats/min; p<0.05, respectively), and normalized oxygen pulse and the heart rate to minute ventilation ratio during maximal exercise. There was no significant difference between those receiving sotalol and those receiving placebo in oxygen deficit (502+/-150 mL vs 425+/-140 mL; p=0.38), maximal VO2 (17.2+/-4.9 mL/kg/min vs 20.4+/-4.7 mL/kg/min; p=0.17), and other gas exchange variables. In patients with AF, oxygen deficit has a fair correlation with VO2 at the anaerobic threshold (r2=0.43; p<0.05) and at maximal exercise (r2=0.45; p<0.05).
In addition to maximal exercise capacity and cardiopulmonary performance, patients with chronic AF without significant structural heart disease had impaired submaximal exercise performance as assessed by VO2 kinetics. These parameters were not significantly affected by sotalol used for rate control.
心房颤动(AF)与运动能力受损有关。摄氧量(VO₂)动力学决定了次极量运动期间的心肺功能,而这在AF患者中可能受损。
研究无结构性心脏病的AF患者的氧动力学和心肺功能,以及口服索他洛尔对这些参数的影响。
招募了20例连续的慢性AF患者(平均年龄56±8岁)。方案设计为随机、单盲、安慰剂对照试验。患者在为期8周的研究期内接受索他洛尔或安慰剂治疗,并在随后的时期接受另一种治疗。在每个阶段结束时,使用恒定负荷和递增负荷方案进行心肺功能测试。纳入16名年龄匹配的正常受试者作为对照。
在恒定次极量运动期间,AF患者的氧亏空更大(425±140 mL,而正常受试者为289±80 mL;p<0.05),达到VO₂的63%的时间(平均反应时间)也延迟(46±15秒,而正常受试者为33±10秒;p<0.05)。与正常受试者相比,慢性AF患者的最大运动心率更高(180±34次/分钟,而正常受试者为153±22次/分钟;p<0.05),但最大VO₂更低(20±4 mL/kg/分钟,而正常受试者为26±6 mL/kg/分钟;p<0.05)。与安慰剂相比,口服索他洛尔降低了静息心率(72±15次/分钟,而安慰剂组为93±22次/分钟;p<0.05)和运动心率(125±27次/分钟,而安慰剂组为180±34次/分钟;p<0.05),并使最大运动时的氧脉搏和心率与分钟通气量之比正常化。接受索他洛尔和接受安慰剂的患者在氧亏空(502±150 mL,而安慰剂组为425±140 mL;p=0.38)、最大VO₂(17.2±4.9 mL/kg/分钟,而安慰剂组为20.4±4.7 mL/kg/分钟;p=0.17)和其他气体交换变量方面无显著差异。在AF患者中,氧亏空与无氧阈值时的VO₂(r²=0.43;p<0.05)和最大运动时的VO₂(r²=0.45;p<0.05)有中度相关性。
除了最大运动能力和心肺功能外,无明显结构性心脏病的慢性AF患者的次极量运动表现也受损,这通过VO₂动力学评估得出。用于心率控制的索他洛尔对这些参数无显著影响。